NEW YORK (S&P Global Ratings) May 21, 2020--S&P Global Ratings said today that its 'BBB-' issuer credit rating and stable outlook on Boston Scientific Corp. (BBB-/Stable/A-3) are unaffected by its proposed $1.5 billion equity issuance, which consists of $750 million in common equity and $750 million in mandatory convertible preferred stock. We expect Boston Scientific to use portion of the combined net proceeds from the offerings to repay in full the remaining $750 million outstanding under its $1.25 billion term loan credit facility maturing on April 2021. The company will use the remaining proceeds for general corporate purposes, which may include refinancing or repayment of other outstanding debt and funding potential future acquisitions and investments. We view the proposed issuance
